Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Pachyonychia Congenita

Palvella Therapeutics, a clinical-stage biopharmaceutical company, has released the topline results from its Phase 3 VAPAUS study of QTORIN™ rapamycin gel for the treatment of Pachyonychia Congenita (PC). The study did not show a treatment effect on the primary endpoint. However, it is important to note that the drug was well-tolerated with no serious adverse events reported. As a result, Palvel..